Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer
CAMBRIDGE, MASS. – [July 24, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.
“The expansion of our leadership team will not only allow us to streamline and optimize our operations, but further execute on our strategic vision to deliver breakthrough treatments to target major unmet needs in cardiovascular medicine,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “Cardiovascular disease is the leading cause of death in both men and women and accounts for one-third of deaths worldwide.1,2 Rebecca’s strategic know-how and operational ingenuity will be critical for Cardurion as we pursue our goal to transform the treatment of cardiovascular disease.”
Rebecca is a highly regarded leader who brings almost 20 years of strategic and operational biotech experience to Cardurion Pharmaceuticals. As chief operating officer, Rebecca will formulate strategies and lead all aspects of operations to maximize value creation. Prior to joining Cardurion Pharmaceuticals, Rebecca served as executive vice president of operations at Prevail Therapeutics, where she led clinical operations and early development planning. Prior to that, Rebecca spent eleven years at Alexion Pharmaceuticals. During her tenure, Rebecca held a wide range of leadership roles in development, project management and manufacturing, including vice president of operations and chief of staff to the CEO. Before Alexion, Rebecca spent six years in clinical operations and medical affairs at Novartis Pharmaceuticals. Rebecca earned her Doctor of Pharmacy from Northeastern University and completed her post-doctoral clinical research fellowship at Northeastern University and Tufts Medical Center. She is a 2017 graduate of the Women in Bio Boardroom Ready program.
“There exists a critical medical need for innovation to overcome the burden of cardiovascular diseases, and I’m pleased to join a world-class team of cardiologists with a deep understanding and desire to advance treatments for patients who are living with heart failure,” said Rebecca Frey, chief operating officer at Cardurion Pharmaceuticals. “I am excited to bring my capability and passion for disciplined execution to Cardurion’s management team, and I look forward to delivering on the company’s strategic priorities.”
For additional information on Cardurion Pharmaceuticals’ leadership team, please visit the company’s website: http://www.cardurion.com.
About Cardurion Pharmaceuticals
Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.
Cardurion Pharmaceuticals’ Forward Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.
The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.